In order for infants in the CASG 103 study to meet the requirements to undergo randomization following the initial program of parenteral acyclovir, they had to possess cerebrospinal liquid that was bad for HSV DNA, as detected by PCR assay, after completion of that regimen. The primary end point of both studies was neurodevelopmental status at 12 months of age, as assessed with the use of the Bayley Scales of Infant Development, second edition. Secondary end points had been two or fewer recurrences of cutaneous lesions during the first 12 several weeks of age and recognition by PCR assay of HSV DNA in the cerebrospinal fluid during or after suppressive therapy. The tertiary end stage was toxic ramifications of grade 2 or higher, as assessed by using the World Health Organization Toxicity Grading Scale.13 All of the infants completed a 14-day course or a 21-day course of parenteral acyclovir, because is the standard of care.14 Infants in both studies were then randomly assigned, in a 1:1 ratio, to oral placebo or acyclovir, in a double-blind fashion.This survey encourages the usage of standard operating techniques and forced period outs to make sure adequate time to perform evaluations or quality assurance at key points in the process. Associates have to acknowledge that delays in initiation of treatment may be essential to allow adequate time for quality assurance checks and to investigate any complications uncovered. Related StoriesAPBI brachytherapy increases overall survival in selected patients with early stage breasts cancerUCLA study finds price variation across entire care process for low-risk prostate cancerRare genetic mutation could improve outcomes in NSCLC patients with brain metastasesThe statement also provides practical guidance that radiation oncology treatment groups may use in their clinics to improve safety.